For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG would like to extend condolences to the family, friends, and colleagues of Dr. Libni Joseph Eapen who passed suddenly last week. Dr. Eapen was a researcher and radiation oncologist at the Ottawa Cancer Centre for the entirety of his career, he dedicated his 66 years to learning, teaching, humour and healing.
Condolences can be left on his obituary page https://www.dignitymemorial.com/obituaries/ottawa-on/libni-eapen-9358605
The Phase 2 clinical trial will analyze blood-based biomarkers versus conventional radiography for cancer patients treated with immunotherapy; findings could change direction of lung cancer treatment
BRC8 MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)" has been centrally activated.
The CCTG Trialblazers raised $7200 as part of the Canadian Cancer Society's Relay For Life "At Home" event.
CCTG investigators are contributing to COVID-19 research by developing and leading innovative, cutting-edge clinical trials to support patients with cancer.
Congratulations to the 2019-2020 New Investigator Cancer Trials Practicum graduates!
There were four recent publications, including the primary publication for CCTG CO.26: A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies.
